GSTC has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
GSTC has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, GlobeStar Therapeutics's Enterprise Value is $1.18 Mil. GlobeStar Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.86 Mil. Therefore, GlobeStar Therapeutics's EV-to-EBIT for today is -0.64.
The historical rank and industry rank for GlobeStar Therapeutics's EV-to-EBIT or its related term are showing as below:
During the past 13 years, the highest EV-to-EBIT of GlobeStar Therapeutics was -0.64. The lowest was -59.80. And the median was -11.24.
Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. GlobeStar Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 was $1.31 Mil. GlobeStar Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.86 Mil. GlobeStar Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -141.39%.
The historical data trend for GlobeStar Therapeutics's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GlobeStar Therapeutics Annual Data | |||||||||||||||||||||
Trend | Sep14 | Sep15 | Sep16 | Sep17 | Sep18 | Sep19 | Sep20 | Sep21 | Sep22 | Sep23 | |||||||||||
EV-to-EBIT | Get a 7-Day Free Trial | -20.03 | -10.01 | -1.75 | -1.90 | -1.16 |
GlobeStar Therapeutics Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
EV-to-EBIT | Get a 7-Day Free Trial | -8.15 | -7.29 | -2.11 | -1.16 | -0.71 |
For the Biotechnology subindustry, GlobeStar Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, GlobeStar Therapeutics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where GlobeStar Therapeutics's EV-to-EBIT falls into.
GlobeStar Therapeutics's EV-to-EBIT for today is calculated as:
EV-to-EBIT | = | Enterprise Value (Today) | / | EBIT (TTM) |
= | 1.184 | / | -1.859 | |
= | -0.64 |
GlobeStar Therapeutics's current Enterprise Value is $1.18 Mil.
GlobeStar Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.86 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GlobeStar Therapeutics (OTCPK:GSTC) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.
GlobeStar Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:
Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) | = | EBIT | / | Enterprise Value (Q: Dec. 2023 ) |
= | -1.859 | / | 1.314775 | |
= | -141.39 % |
GlobeStar Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 was $1.31 Mil.
GlobeStar Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.86 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of GlobeStar Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
James C Katzaroff | director, officer: CEO | 719 JADWIN AVE., RICHLAND WA 99352 |
William J Farley | director | 468 ALBERN AVE, OCEANSIDE NY 11572 |
Robert Chicoski | officer: CFO | 145 NEWTON ROAD, HAVERHILL MA 01830 |
Alex K Blankenship | director, officer: CEO, Pres., Secr., Treas. | 14001 WALDEN RD., SUITE 600, MONTGOMERY TX 77356 |
Brent Atwood | 10 percent owner | 5000 RIVERSIDE DR STE100E, IRVING TX 75039 |
Bruce C Badeau | director | 770 S. POST OAK LN., STE. 360, HOUSTON TX 77056 |
Robert W Fryer | director | 1520 ENCLAVE, # 1208, HOUSTON TX 77077 |
Robert Federowicz | director, officer: Interim CEO & Chairman | 495 GRAND BLVD., SUITE 206, MIRAMAR BEACH FL 32550 |
From GuruFocus
By ACCESSWIRE ACCESSWIRE • 10-11-2021
By ACCESSWIRE ACCESSWIRE • 06-09-2021
By ACCESSWIRE ACCESSWIRE • 07-15-2021
By Marketwired Marketwired • 03-09-2020
By ACCESSWIRE ACCESSWIRE • 02-04-2022
By ACCESSWIRE • 11-02-2023
By ACCESSWIRE ACCESSWIRE • 03-01-2022
By ACCESSWIRE ACCESSWIRE • 05-11-2021
By ACCESSWIRE ACCESSWIRE • 07-06-2021
By ACCESSWIRE ACCESSWIRE • 05-04-2021
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.